secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0001438533-23-000050
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere announces successful pre-NDA for FILSPARI in IgAN, FSGS setback, and 20% workforce reduction
--------------------------------------------------------------------------------

- Successful pre-NDA meeting for FILSPARI in IgA nephropathy; sNDA submission for full approval planned for Q1 2024.
- Two-year Phase 3 DUPLEX results insufficient for FSGS sNDA; additional analyses planned with FDA re-engagement in 2024.
- Company approves ~20% workforce reduction (non-field employees) as part of strategic reorganization; charges estimated $12-14M.
- Majority of restructuring charges expected in Q4 2023; cash payments substantially complete by Q1 2024.
- Focus on FILSPARI launch and pegtibatinase Phase 3 program for HCU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000050/0001438533-23-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000050/tvtx-20231130.htm
  HTML page:      https://secwatch.observer/filing/0001438533-23-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer